High Note Wealth’s Corcept Therapeutics CORT Stock Holding History

High Note Wealth’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-28	Closed	-$1.41K	–	896
2024 Q4	$1.41K	Buy	+28	New	+$1.47K	﹤0.01%	735

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

High Note Wealth's CORT Position: Q1 2025 in Review

High Note Wealth sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 28 shares — an estimated $1.41K sold.

High Note Wealth first reported a position in CORT in Q4 2024 and held it in 1 quarter. The position peaked at $1.41K in Q4 2024. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

High Note Wealth reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
High Note Wealth sold 28 Corcept Therapeutics shares in Q1 2025, an estimated $1.41K.
High Note Wealth first reported a position in Corcept Therapeutics in Q4 2024 and held it in 1 quarter.
High Note Wealth's Corcept Therapeutics position peaked at $1.41K in Q4 2024.
422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on High Note Wealth's 13F filing for Q1 2025, filed 1 May 2025.